Picibanil

Subscribe to Selected New Research on Picibanil

944 relevant articles (160 outcomes, 129 trials/studies) found for this Bio-Agent

Description: A lyophilized preparation of a low-virulence strain (SU) of Streptococcus pyogenes (S. hemolyticus), inactivated by heating with penicillin G. It has been proposed as a noncytotoxic antineoplastic agent because of its immune system-stimulating activity.

Also Known As:

NSC-B116209; OK-432; Picibanyl; Streptococcal OK-432; Streptococcal Preparation OK-432; NSC B116209; NSCB116209; OK 432; OK432; Streptococcal OK 432; Streptococcal OK432; Streptococcal Preparation OK 432; Streptococcal Preparation OK432

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 314

Experts

1.	Okamoto, Masato: 9 articles (08/2007 - 11/2002)
2.	Ryoma, Yoshiki: 8 articles (08/2007 - 09/2002)
3.	Sato, Mitsunobu: 8 articles (09/2006 - 11/2002)
4.	Oshikawa, Tetsuya: 8 articles (09/2006 - 11/2002)
5.	Tano, Tomoyuki: 6 articles (05/2006 - 11/2002)
6.	Moriya, Yoichiro: 5 articles (05/2006 - 11/2002)
7.	Ahmed, Sharif Uddin: 5 articles (10/2005 - 11/2002)
8.	Roh, Jong-Lyel: 4 articles (09/2008 - 02/2006)
9.	Saito, Motoo: 4 articles (05/2006 - 11/2002)
10.	Sasai, Akiko: 3 articles (05/2006 - 11/2004)

Related Diseases

1.	Neoplasms (Cancer) 11/01/1987 - "However, it was also observed that most of the R1-3B3- cells that killed MADB106 tumor cells were: 1) phenotypically or functionally different from either cytotoxic T-cells or typical NK cells; 2) observed only in MADB106 tumor-bearing rats challenged with OK-432; 3) not present on day 1-2 following OK-432 injection, the time when YAC-1 killing was maximally augmented; and 4) present in high numbers in a secondary response following reinoculation of the MADB106 tumor cells into cured rats. " 11/01/1992 - "The present study was designed to determine the optimal therapeutic protocol for OK-432, a streptococcal preparation, and to clarify the kinetics of various immunological parameters following intracutaneous administration of OK-432 in 39 disease-free postoperative patients with early cancer. " 09/01/1991 - "A randomized prospective study of 1011 gastrectomized cancer patients treated with oral OK432 showed significantly good results, especially in n(+) cases with curative resection. " 10/01/2005 - "Anti-tumor effect of OK-432 in TLR9-deficient mice was significantly but partially reduced as compared with that in wild-type mice, while the effect of OK-432 was almost completely eliminated in TLR4-deficient mice. " 12/15/1994 - "However, analysis based on stage showed that a preoperative intratumoral injection of OK-432 significantly improved the 5-year survival rate of patients with Stage III cancer (P = 0.0229), at 47.7% for the OK-432 group and 27.5% for the control group. " Order ALL the reference details at left...
2.	Stomach Neoplasms (Stomach Cancer) 07/01/1994 - "Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion." 04/01/1987 - "A long term small-dose intratumoral administration of OK-432 seemed to be effective for a local recurrence of gastric cancer." 09/01/2002 - "Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials." 01/01/1994 - "In this negative trial, there was no improvement in survival time with the addition of OK-432 to MMC and UFT for patients with gastric cancer and peritoneal dissemination." 04/01/1988 - "The clinical efficacy of oral OK-432 on gastric cancer patients has been examined by a controlled randomized trial involving a total of about 1000 cases. " Order ALL the reference details at left...
3.	Lymphangioma (Cavernous Lymphangioma) 03/01/1991 - "The results suggest that intralesional OK-432 therapy is effective for most unresectable lymphangiomas." 07/01/2009 - "Although OK-432 is predictably-effective against lymphangioma, it should not perform be applied without careful consideration." 03/01/2003 - "CONCLUSIONS: OK-432 injection was effective in approximately one third of children with lymphangioma. " 04/01/2000 - "OK-432 proved to be effective for primitive as well as for residual and recurrent lymphangioma. " 07/01/2007 - "CONCLUSION: The results of this study so far indicate that OK-432 is an effective and safe tool for the treatment of lymphangioma of head and neck region. " Order ALL the reference details at left...
4.	Neoplasm Metastasis (Metastasis) 08/01/1992 - "We concluded that intra-lymph nodal injection of OK-432 is very effective for treating lymph node metastasis." 10/01/1995 - "As a result, MLN metastasis was significantly suppressed and survival rate was significantly improved in every protocol as compared to mice without OK-432 administration. " 01/01/1993 - "In stage II without lymph node metastasis, 5-year disease free rate was significantly higher in the OK-432 group." 02/01/2001 - "This study showed that only one time preoperative OK-432 it, particularly when it triggers TILs, is effective for reduction of regional lymph node metastasis. " 10/01/1995 - "Administration of OK-432 prior to the surgical stress or ASGM 1 was at least partly effective for prevention of the hepatic metastasis and prolonged the survival of the inoculated mice. " Order ALL the reference details at left...
5.	Carcinoma (Carcinomatosis) 07/01/1992 - "The results indicate that OK-432 combined with MMC may be effective against stage III gastric carcinoma, when these agents are used probably in an appropriate combination." 01/01/1986 - "As to the absolute number of lymphocytes, improvement in the long-term NPC group was delayed in comparison to that of another head and neck carcinoma group given long-term OK-432 treatment. " 01/01/1982 - "A patient with gastric carcinoma improved remarkably on intraperitoneal OK-432 therapy." 11/15/1998 - "CONCLUSIONS: The results of this study show that OK-432 may be an active, well tolerated agent for the treatment of curatively resected gastric carcinoma. " 11/01/1987 - "In the present study, the antigenic phenotype and target cell specificity of the cytotoxic lymphocytes observed in F344 rats following the ip inoculation of a syngeneic MADB106 mammary carcinoma and the single injection of OK-432 were examined. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Picibanil
2.	krestin (PSK)
3.	Interleukin-2 (IL2)
4.	Fluorouracil (Carac)
5.	Tegafur
6.	Fibrinogen (Factor I)
7.	Mitomycin (Mitomycin-C)
8.	Cisplatin (Platino)
9.	Carbazilquinone (Carboquone)
10.	Cyclophosphamide (Cytoxan)

Related Therapies and Procedures

1.	Immunotherapy
2.	Sclerotherapy
3.	Drug Therapy (Chemotherapy)
4.	Intralesional Injections
5.	Injections

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>